Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CCT-617
- Development stage
- Preclinical
- Lead developer
- Canary Cure
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
CCT-617 is a preclinical-stage small interfering RNA (siRNA) therapeutic being developed by Canary (also known as Canary Cure or Canary Global) for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The drug is part of Canary's Thermogenic Adipose Reprogramming platform, which utilizes siRNA to modulate thermogenic pathways in adipose tissue. By silencing specific genetic targets involved in metabolic regulation, CCT-617 aims to reprogram white adipose tissue into a more metabolically active state, thereby increasing energy expenditure and improving systemic metabolic health. As of 2024, the program remains in the preclinical development phase.
Beyond the preview
Go deeper on CCT-617.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CCT-617.